In Vivo Studies

TAT-Cx43266-283 reduces the growth, invasion, and progression of malignant gliomas and enhances the survival of glioma-bearing mice without exerting toxicity in endogenous brain cells, which suggests that this peptide could be considered as a new clinical therapy for high-grade gliomas.

Jaraíz-Rodríguez, M., Talaverón, R., García-Vicente, L., Pelaz, S. G., Domínguez-Prieto, M., Álvarez-Vázquez, A., Flores-Hernández, R., Sin, W. C., Bechberger, J., Medina, J. M., Naus, C. C., & Tabernero, A. (2020). Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo. Neuro-oncology, 22(4), 493–504. https://doi.org/10.1093/neuonc/noz243

Animals

Albino Wistar rats, nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, and C57BL/6 mice were obtained from the animal facility of the University of Salamanca and the University of British Columbia. The animal procedures were approved by the ethics committee of the University of Salamanca and the Junta de Castilla y León and were carried out in accordance with European Community Council directives (2010/63/UE), Spanish law (RD 53/2013 BOE 34/11370–420, 2013) for the use and care of laboratory animals, and the University of British Columbia Animal Care Committee (protocol number: A14-0183) and performed in accordance with the guidelines established by the Canadian Council on Animal Care.

Myriam Jaraíz-Rodríguez, Rocío Talaverón, Laura García-Vicente, Sara G Pelaz, Marta Domínguez-Prieto, Andrea Álvarez-Vázquez, Raquel Flores-Hernández, Wun Chey Sin, John Bechberger, José M Medina, Christian C Naus, Arantxa Tabernero, Connexin43 peptide, TAT-Cx43_266–283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo, Neuro-Oncology, Volume 22, Issue 4, April 2020, Pages 493–504, https://doi.org/10.1093/neuonc/noz243

Doses and Routes of Administration Effective and Safe in Mice: